Royalty Pharma PLC (RPRX) reported robust financial results for the third quarter of fiscal 2025, surpassing analyst expectations. The company's earnings per share (EPS) reached $1.17, exceeding the consensus estimate of $1.06 by $0.11. Revenue matched expectations at $0.8 billion.
The results highlight Royalty Pharma's strong operational performance within the pharmaceuticals sector, where it engages in providing drug development services. The company collaborates with innovators across the industry, from academic institutions to global pharmaceutical firms, funding late-stage clinical trials and new product launches in exchange for future royalties. Its portfolio includes royalties on over 35 commercial products, such as Vertex’s Trikafta and GSK’s Trelegy.
Royalty Pharma will host an earnings conference call to discuss these results further and provide insight into its business performance. Investors are encouraged to review the full earnings release and listen to management's commentary for a comprehensive understanding of the quarter's performance and future outlook.
As of November 8, 2025, Royalty Pharma holds a market capitalization of $22.55 billion, with a price-to-earnings (P/E) ratio of 22.09 and a trailing EPS of 1.74. The company anticipates its next earnings report on August 3, 2026, with an EPS estimate of 1.4382 and revenue expected to remain at $0.8 billion.